Climb Bio (CLYM) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$13.5M

Net income growth (year over year)

−55.76%

Net margin

—

Return on equity

−27.10%

EPS (trailing twelve months)

−$0.82

Book value per share

$4.17

P/E (trailing twelve months)

—

Price to book

2.47

Debt to assets

2.74%

Payout ratio

—

Dividend yield

—

Company profile

Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.

• How do I buy stock in Climb Bio (CLYM)?

  CLYM trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.